Literature DB >> 25380786

Effectiveness of CT assists for intraarterial chemotherapy: therapeutic outcome of chemoradiation for advanced head and neck cancer extending across the anatomical midline.

Daisuke Yunaiyama1, Kazuhiro Saito, Tomokazu Funatsu, Hidetsugu Nakayama, Akira Shimizu, Hiroyuki Ito, Mamoru Suzuki, Soichi Akata, Koichi Tokuuye.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the effectiveness of CT assist for intraarterial chemotherapy in relation to the therapeutic outcomes of intraarterial chemoradiation for advanced head and neck cancer with extension across the anatomical midline (EAM).
METHODS: This retrospective study evaluated 64 consecutive patients. In total, 26 and 38 patients had cancer with or without EAM, respectively. These patients underwent an intraarterial cisplatin infusion (200 mg/m(2), days 1 and 35) and intravenous 5-FU infusion (800 mg/m(2), days 1-5 and 36-39) concomitantly with radiotherapy. Angiography-assisted CT was performed to confirm complete coverage during the intraarterial chemotherapy. The accuracy of diagnosing tumor vessels by digital subtraction angiography (DSA) was evaluated using receiver-operating characteristic analysis by two radiologists. The overall survival and locoregional control rates were calculated by the Kaplan-Meier method.
RESULTS: DSA was not useful for diagnosing tumor vessels. The 2-year overall survival rates for the patients with cancer with or without EAM were 83 and 90 %, while the 2-year locoregional control rates were 95 and 82 %, respectively. Locoregional control or the overall survival rates showed no significant differences.
CONCLUSIONS: Intraarterial chemotherapy using angiography-assisted CT during chemoradiation therapy can achieve comparable therapeutic outcomes for cancer with and without EAM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25380786     DOI: 10.1007/s11604-014-0370-5

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  17 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Evaluation of vascular supply with cone-beam computed tomography during intraarterial chemotherapy for a skull base tumor.

Authors:  Reiichi Ishikura; Kumiko Ando; Yuki Nagami; Satoshi Yamamoto; Koui Miura; Ajaya Raj Pande; Tosyiko Yamano; Shozo Hirota; Norio Nakao
Journal:  Radiat Med       Date:  2006-06

3.  Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.

Authors:  Frank J P Hoebers; Frank A Pameijer; Josien de Bois; Wilma Heemsbergen; Alfons J M Balm; Jan H Schornagel; Coen R N Rasch
Journal:  Head Neck       Date:  2008-09       Impact factor: 3.147

4.  Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience.

Authors:  K T Robbins; P Kumar; W F Regine; F S Wong; A B Weir; P Flick; L E Kun; R Palmer; T Murry; J Fontanesi; R Ferguson; R Thomas; W Hartsell; C U Paig; G Salazar; L Norfleet; C B Hanchett; V Harrington; H B Niell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-05-01       Impact factor: 7.038

5.  Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer.

Authors:  Patrick D Maguire; Michael Papagikos; Sue Hamann; Charles Neal; Martin Meyerson; Neil Hayes; Peter Ungaro; Kenneth Kotz; Marion Couch; Hoke Pollock; Joel Tepper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-08       Impact factor: 7.038

6.  IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.

Authors:  Michael E Montejo; Dennis C Shrieve; Brandon G Bentz; Jason P Hunt; Luke O Buchman; Neeraj Agarwal; Ying J Hitchcock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-16       Impact factor: 7.038

7.  A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx.

Authors:  K T Robbins; J Fontanesi; F S Wong; D Vicario; S Seagren; P Kumar; R Weisman; P Pellitteri; J R Thomas; P Flick; R Palmer; A Weir; C Kerber; T Murry; R Ferguson; G Los; L Orloff; S B Howell
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1996-08

8.  Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients.

Authors:  K T Robbins; P Kumar; F S Wong; W F Hartsell; P Flick; R Palmer; A B Weir; H B Neill; T Murry; R Ferguson; C Hanchett; F Vieira; A Bush; S B Howell
Journal:  Head Neck       Date:  2000-10       Impact factor: 3.147

9.  First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial.

Authors:  Annemieke H Ackerstaff; Alfons J M Balm; Coen R N Rasch; Jan Paul de Boer; Ruud Wiggenraad; Derk H F Rietveld; R Theo Gregor; Robert Kröger; Frans J M Hilgers
Journal:  Head Neck       Date:  2009-01       Impact factor: 3.147

10.  High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer.

Authors:  Alfons J M Balm; Coen R N Rasch; Jan H Schornagel; Frans J M Hilgers; Ronald B Keus; Leo Schultze-Kool; Annemieke H Ackerstaff; Wim Busschers; I Bing Tan
Journal:  Head Neck       Date:  2004-06       Impact factor: 3.147

View more
  1 in total

1.  Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy.

Authors:  Gunjan Srivastava; Raj Thani Somasundaram; Paul G Walfish; Ranju Ralhan
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.